Drug interactions
Inotuzumab + Sorafenib
Severity: Major
Inotuzumab and Sorafenib: major interaction.
Last updated Sources: US FDA label
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both agents can prolong the QT interval, which raises the risk of torsades de pointes. Inotuzumab labeling advises monitoring when it is combined with other QT-prolonging drugs.
What this interaction means in plain words
Inotuzumab and Sorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Additive pharmacodynamic QT prolongation.
What to do
Obtain ECGs and electrolytes before starting and periodically during treatment. Correct hypokalemia and hypomagnesemia.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Inotuzumab and Sorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
References
Other interactions of Sorafenib
Frequently asked questions
Can I take Inotuzumab with Sorafenib?
MediHelp rates the interaction as major. Inotuzumab and Sorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both agents can prolong the QT interval, which raises the risk of torsades de pointes. Inotuzumab labeling advises monitoring when it is combined with other QT-prolonging drugs.
How serious is the interaction between Inotuzumab and Sorafenib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain ECGs and electrolytes before starting and periodically during treatment. Correct hypokalemia and hypomagnesemia.
What other medicines interact with Sorafenib?
MediHelp also lists interactions of Sorafenib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Sorafenib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
